hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Indian firms, Clinton Foundation sign deal on malaria drugs

Author: Indo Asian News Service, Published on: 18 July 2008

Four Indian and two Chinese companies will cut the price of a key malaria drug and control rates of a vital ingredient following a pact signed Thursday with the US-based Clinton Foundation…The Indian companies are generic drug firms Cipla and IPCA Laboratories… and Calyx and Mangalam Drugs…China’s Holleypharm and PIDI Standard grow the plants…“This agreement will reduce the prices for ACT drugs by 30 percent,” [former U.S. President Bill] Clinton said while announcing the deal...The lower prices for the ACT drugs will be available to the 69 countries in Africa, Asia, Latin America and the Caribbean that make up the Clinton HIV-AIDS Initiative (CHAI) purchasing consortium…[refers also to Novartis]

Read the full post here

Related companies: Calyx Cipla Holleypharm IPCA Laboratories Mangalam Novartis PIDI Standard